QuidelOrtho Corporation

Equities

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
17.10 ^USD	-4.58%		-20.13%	-40.13%

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI

Published on 02/12/2026 at 03:36 am GMT - Modified on 02/16/2026 at 10:49 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning or good afternoon. Welcome to the QuidelOrtho Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI
02-12	UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating	MT
02-12	QuidelOrtho Corporation, Q4 2025 Earnings Call, Feb 11, 2026
02-11	QuidelOrtho Q4 Earnings Fall, Revenue Rises; Issues Guidance	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q4 Revenue $723.6M, vs. FactSet Est of $700.7M	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q4 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.42	MT
02-11	Joseph M. Busky to Retire as Chief Financial Officer of QuidelOrtho Corporation, Effective June 30, 2026	CI
02-11	QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2026	CI
02-11	QuidelOrtho Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
02-05	QuidelOrtho Corp Announces Departure of Director Matthew W. Strobeck	CI
01-21	UBS Adjusts QuidelOrtho Price Target to $35 From $31, Maintains Neutral Rating	MT
12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-06	QuidelOrtho Corporation, Q3 2025 Earnings Call, Nov 05, 2025